ArticleAntibiotics (Basel, Switzerland)2021
Enrofloxacin Dose Optimization for the Treatment of Colibacillosis in Broiler Chickens Using a Drinking Behaviour Pharmacokinetic Model.
Article in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- A systematic review and meta-analysis on the efficacy of antibiotic treatment in controlling colibacillosis in broiler production.PloS one · 2025Pooled it
- Predicted PK/PD inadequacy of amoxicillin delivered in drinking water against respiratory pathogens in post-weaning piglets: can time-restricted dosing improve animals' exposure and potential treatment efficacy?Veterinary and animal science · 2026Article
- Active-controlled commercial field evaluation of an independently developed fluralaner oral solution for poultry red mite control in laying hens.Poultry science · 2026Article
- Comparative efficacy of second- and third-generation fluoroquinolone antibiotics against systemic Escherichia coli infection in broiler chickens in Qalyubia Governorate, Egypt.Scientific reports · 2026Article
- Phenotypic and genomic analysis of the emerging poultry pathogenMicrobial genomics · 2025Article
- Pharmacokinetics, pharmacodynamic efficacy prediction indices, and Monte Carlo simulations of enrofloxacin for the treatment of colibacillosis in broiler chickens.Open veterinary journal · 2025Article
- Fate of fluoroquinolones in field soil environment after incorporation of poultry litter from a farm with enrofloxacin administration via drinking water.Environmental science and pollution research international · 2024Article
- Targeted dosing for susceptible heteroresistant subpopulations may improve rational dosage regimen prediction for colistin in broiler chickens.Scientific reports · 2023Article
- Population Pharmacokinetics of Doxycycline, Administered Alone or with N-Acetylcysteine, in Chickens with ExperimentalPharmaceutics · 2022Article
- Influence of Huangqin Decoction on the immune function and fecal microbiome of chicks after experimental infection with Escherichia coli O78.Scientific reports · 2022Article
- Antibiotic Resistance in Bacteria-A Review.Antibiotics (Basel, Switzerland) · 2022Review
- Dose-dependent impact of enrofloxacin on broiler chicken gut resistome is mitigated by synbiotic application.Frontiers in microbiology · 2022Article
- Absorption of N-acetylcysteine in Healthy andVeterinary sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Enrofloxacin is frequently administered via drinking water for the treatment of colibacillosis in broiler chickens. However, the EMA/CVMP has urged to re-evaluate historically approved doses, especially for antimicrobials administered via drinking water. In response, the objectives of this study were two-fold. First, to evaluate the pharmacokinetics (PK) of enrofloxacin following IV, PO and drinking water administration. Second, to predict the efficacy of a range of doses in the drinking water for the treatment of APEC infections. For the first objective, PK parameters were estimated by fitting a one-compartmental model with a zero-order IV infusion and an oral absorption lag function to the simultaneously modelled IV and PO data. After fixing these parameter values, a drinking behaviour pharmacokinetic (DBPK) model was developed for the description and prediction of drinking water PK profiles by adding three model improvements (different diurnal and nocturnal drinking rates, inter-animal variability in water consumption and taking account of dose non-proportionality). The subsequent simulations and probability of target attainment (PTA) analysis predicted that a dose of 12.5 mg/kg/24 h is efficacious in treating colibacillosis with an MIC up to 0.125 μg/mL (ECOFF), whereas the currently registered dose (10 mg/kg/24 h) reaches a PTA of 66% at ECOFF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.